Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6605567.pdf
Reference18 articles.
1. Baccala Jr A, Hedgepeth R, Kaouk J, Magi-Galluzzi C, Gilligan T, Fergany A (2007) Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol 14: 1095–1097
2. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25: 1760–1764
3. Bex A, Van der Veldt AA, Blank C, Van den Eertwegh AJ, Boven E, Horenblas S, Haanen J (2009) Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 27: 533–539
4. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25: 1753–1759
5. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370: 2011–2019
Cited by 142 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT;Health Technology Assessment;2024-08
2. Gastrointestinal stromal tumors with an uncommon primary mutation responded well to imatinib;Cancer Pathogenesis and Therapy;2024-08
3. A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib;Journal of Cancer Research and Clinical Oncology;2024-02-19
4. Role of enhancement modifications in evaluating tumor response to immunotherapy in metastatic renal cell carcinoma;Tumori Journal;2023-07-28
5. Evaluation and Prediction of Treatment Response for Hepatocellular Carcinoma;Magnetic Resonance in Medical Sciences;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3